Clinical biological remission induced by rituximab in acute refractory chronic relapsing TTP

Thrombosis Research

Volumn 126, Issue 2, 2010, Pages

  Lombardi, Anna Maria ^a   Berti De Marinis, Giulia ^a   Scandellari, Raffaella ^a   Magalini, Francesca ^b   Sansoni, Paolo ^b   Ballerini, Pier Ferruccio ^c   Vettore, Silvia ^a   Candeo, Nicole ^a   Marson, Piero ^d   De Silvestro, Giustina ^d   Fabris, Fabrizio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

^c IRCCS E Medea Scientific Institute   (Italy)

^d UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

ADAMTS13; Autoantibodies; Plasma exchange; Rituximab; Thrombotic thrombocytopenic purpura; TTP

Indexed keywords

AUTOANTIBODY; CHLORPHENIRAMINE; FRESH FROZEN PLASMA; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PARACETAMOL; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ABSENCE OF SIDE EFFECTS; ADULT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; APHERESIS; AUTOIMMUNE DISEASE; CASE REPORT; CHRONIC DISEASE; CYTOPENIA; DRUG INFUSION; ENZYME ACTIVITY; FEMALE; HUMAN; LETTER; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

ACUTE DISEASE; ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; FEMALE; HUMANS; MALE; MIDDLE AGED; PURPURA, THROMBOTIC THROMBOCYTOPENIC; REMISSION INDUCTION;

EID: 77955716369     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.02.005     Document Type: Letter

References (25)

1. H.M. Tsai, and E.C. Lian Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura N Engl J Med 339 1998 1585 1594
2. M. Furlan, R. Robles, M. Solenthaler, M. Wassmer, P. Sandoz, and B. Lämmle Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura Blood 89 1997 3097 3103
3. M. Furlan, R. Robles, M. Galbusera, G. Remuzzi, P.A. Kyrle, and B. Brenner von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome N Engl J Med 339 1998 1578 1584 (Pubitemid 28536132)
4. H.M. Tsai, M. Raoufi, W. Zhou, E. Guinto, N. Grafos, and S. Ranzurmal ADAMTS13-binding IgG are present in patients with thrombotic thrombocytopenic purpura Thromb Haemost 95 2006 886 892
5. F. Scheiflinger, P. Knöbl, B. Trattner, B. Plaimauer, G. Mohr, and M. Dockal Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura Blood 102 2003 3241 3243
6. G.A. Rock, K.H. Shumak, N.A. Buskard, V.S. Blanchette, J.G. Kelton, and R.C. Nair Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group N Engl J Med 325 1991 393 397
7. F. Fakhouri, J.P. Vernant, A. Veyradier, M. Wolf, G. Kaplanski, and R. Binaut Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases Blood 106 2005 1932 1937
8. E. Bresin, S. Gastoldi, E. Daina, D. Belotti, E. Pogliani, and P. Perseghin Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies Thromb Haemost 101 2009 233 238
9. A. Ahmad, A. Aggarwal, D. Sharma, H.P. Dave, V. Kinsella, and M.E. Rick Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP) Am J Hematol 77 2004 171 176
10. F. Peyvandi, S. Lavoretano, R. Palla, H.B. Feys, K. Vanhoorelbeke, and T. Battaglioli ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission Haematologica 93 2008 232 239
11. K. Kokame, Y. Nobe, Y. Kokubo, A. Okayama, and T. Miyata FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay Br J Haematol 129 2005 93 100
12. H.T. Ling, J.J. Field, and M.A. Blinder Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature Am J Hematol 84 2009 418 421
13. S. Jasti, T. Coyle, T. Gentile, L. Rosales, and B. Poiesz Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature J Clin Apher 23 2008 151 156
14. L. Scaramucci, P. Niscola, R. Palumbo, M. Giovannini, M. Ales, and A. Tendas Rapid response and sustained remission by rituximab in four cases of plasma-exchange-failed acute thrombotic thrombocytopenic purpura Int J Hematol 89 2009 398 399
15. S. Sallah, A. Husain, J.Y. Wan, and N.P. Nguyen Rituximab in patients with refractory thrombotic thrombocytopenic purpura J Thromb Haemost 2 2004 834 836
16. S. Kosugi, M. Matsumoto, Y. Ohtani, H. Take, H. Ishizashi, and Y. Fujimura Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura Int J Hematol 81 2005 433 436
17. S. Hagel, J. Jantsch, U. Budde, J.R. Kalden, K.U. Eckardt, and R. Veelken Treatment of acquired thrombotic thrombocytopenic purpura (TTP) with plasma infusion plus rituximab Thromb Haemost 100 2008 151 153
18. A. Rüfer, D. Brodmann, M. Gregor, J.A. Kremer Hovinga, B. Lämmle, and W.A. Wuillemin Rituximab for acute plasma-refractory thrombotic thrombocytopenic purpura. A case report and concise review of the literature Swiss Med Wkly 137 2007 518 524
19. M. Scully, H. Cohen, J. Cavenagh, S. Benjamin, R. Starke, and S. Killick Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13 Br J Haematol 136 2007 451 461
20. S.K. Vesely, J.N. George, B. Lämmle, J.D. Studt, L. Alberio, and M.A. El-Harake ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients Blood 102 2003 60 68
21. P. Coppo, M. Wolf, A. Veyradier, A. Bussel, S. Malot, and G.A. Millot Schlemmer B; Réseau d'Etude des Microangiopathies Thrombotiques de l'Adulte. Prognostic value of inhibitory anti-ADAMTS13 antibodies in adult-acquired thrombotic thrombocytopenic purpura Br J Haematol 132 2006 66 74
22. D. Provan, T. Butler, M.L. Evangelista, S. Amadori, A.C. Newland, and R. Stasi Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults Haematologica 92 2007 1695 1698
23. F. Zaja, M.L. Battista, M.T. Pirrotta, S. Palmieri, M. Montagna, and N. Vianelli Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura Haematologica 93 2008 930 933
24. J. Chemnitz, A. Draube, C. Scheid, P. Staib, A. Schulz, and V. Diehl Successful treatment of severe thrombotic thrombocytopenic purpura with the monoclonal antibody rituximab Am J Hematol 71 2002 105 108
25. R. Ram, I. Ben-Bassat, O. Shpilberg, A. Polliack, and P. Raanani The late adverse events of rituximab therapy - rare but there! Leuk Lymphoma 50 2009 1083 1095